Status:
NO_LONGER_AVAILABLE
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Lead Sponsor:
Seagen Inc.
Brief Summary
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03424473
Last Update
February 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.